Bionano Genomics (BNGO) EBT Margin (2017 - 2026)

Bionano Genomics has disclosed EBT Margin across 10 years of filings, most recently posting 90.76% for Q2 2026.

• In Q2 2026, EBT Margin rose 1093.0% year-over-year to 90.76%; the TTM figure through Jun 2026 stood at 106.77% (up 16570.0% YoY), while the FY2025 annual figure was 92.78%, up 27251.0% from the prior year.
• EBT Margin came in at 90.76% for Q2 2026 at Bionano Genomics, up from 124.02% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 47.93% in Q1 2025 to a low of 1207.63% in Q3 2023.
• Average EBT Margin over 5 years is 366.12%, with a median of 384.13% recorded in 2023.
• Year-over-year, EBT Margin sank 76751 bps in 2023 and soared 61294 bps in 2025.
• Over 5 years, EBT Margin stood at 448.84% in 2022, then gained by 9 bps to 409.73% in 2023, then jumped by 39 bps to 251.89% in 2024, then soared by 60 bps to 100.87% in 2025, then grew by 10 bps to 90.76% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 90.76% in Q2 2026, 124.02% in Q1 2026, and 100.87% in Q4 2025.